In a report released yesterday, Brandon Couillard from Jefferies reiterated a Buy rating on Nant Health (NASDAQ: NH), with a price target of $4. The company’s shares opened today at $2.39, close to its 52-week low of $2.22.
According to TipRanks.com, Couillard is a top 100 analyst with an average return of 27.6% and a 73.2% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, DENTSPLY SIRONA Inc, and Organovo Holdings.
Nant Health has an analyst consensus of Moderate Buy, with a price target consensus of $4, which is a 67.4% upside from current levels. In a report issued on August 9, Cowen & Co. also reiterated a Buy rating on the stock with a $4 price target.
.
See today’s analyst top recommended stocks >>
Based on Nant Health’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $23.4 million. In comparison, last year the company had a GAAP net loss of $70.06 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NantHealth, Inc. ooperates as an evidence-based, personalized healthcare company, which provides treatment for critical diseases such as cancer. It is based on personalized healthcare approach that integrates novel diagnostics with large scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine.
